The New Drugs and Clinical Trials Amendment Rules- 2026

“Indirect Tax I Indirect Tax Litigation I Customs & FTP I Central Licensing I Arbitration I Advisory”

Dated: 28.01.2026

The New Drugs and Clinical Trials Amendment Rules- 2026

The Ministry of Health and Family Welfare, Government of India, has introduced significant amendments to the New Drugs and Clinical Trials Rules, 2019, through the notification G.S.R. 46(E) dated January 20, 2026. These amendments aim to streamline the regulatory framework for the manufacturing and clinical trials of new drugs and investigational new drugs in India. Here’s a detailed overview of the changes and their implications.

Background

The New Drugs and Clinical Trials Rules, 2019, were first notified on March 19, 2019, under the Drugs and Cosmetics Act, 1940. These rules were last amended on September 19, 2024, via notification G.S.R. 581(E). The latest amendments, effective 45 days from January 20, 2026, introduce new provisions and modifications to enhance efficiency and compliance in the drug development and clinical trial process.

Key Amendments in the 2026 Rules

1. Introduction of Prior Intimation 

One of the most significant changes is the inclusion of “prior intimation” alongside “permission” in several rules. This amendment simplifies the process for manufacturing new drugs or investigational new drugs for analytical and non-clinical testing. Applicants can now submit an online application in Form CT-10 as prior intimation to the Central Licensing Authority, and upon acknowledgment, they can proceed with manufacturing. This applies to drugs excluding categories such as sex hormones, cytotoxic drugs, beta lactum, biologics with live microorganisms, and narcotics and psychotropic drugs.

2. Reduced Timelines

The amendments have reduced the timeline for processing applications under rules 53 and 60 from “ninety working days” to “forty-five working days.” This change is expected to expedite the approval process for clinical trials and manufacturing of new drugs, thereby fostering innovation and reducing delays in drug development.

3. Enhanced Record-Keeping and Compliance

The amendments emphasize stricter record-keeping and compliance requirements for manufacturers. For instance:

Manufacturers must maintain detailed records of the quantity of drugs manufactured, supplied, and used for specified purposes.
Any unused, damaged, expired, or substandard drugs must be destroyed, with proper documentation of the action taken.

4. Suspension or Cancellation of Permissions 

The Central Licensing Authority now has the power to suspend or cancel permissions or acknowledgments of prior intimation if the holder fails to comply with the provisions of the Act and rules. The affected party can appeal to the Central Government within 60 days (for new drugs) or 45 days (for active pharmaceutical ingredients) of receiving the order.

5. Labeling Requirements

The amendments mandate that manufacturers indicate the name and address of the manufacturer and the recipient on the label of the container. Additionally, the scientific name of the drug or a reference for identification must be included, along with the purpose for which the drug is manufactured.

6. Updates to Forms 

The amendments have updated several forms in the Eighth Schedule, including Forms CT-10, CT-12, and CT-13. These forms now include provisions for “prior intimation” alongside “permission,” reflecting the streamlined process introduced by the amendments.

Implications of the Amendments

The New Drugs and Clinical Trials (Amendment) Rules, 2026, are expected to have a significant impact on the pharmaceutical and clinical research industry in India. Key implications include:

Faster Approvals: The reduction in processing timelines will enable quicker approvals for clinical trials and manufacturing, accelerating the development of new drugs and treatments.
Simplified Procedures: The introduction of prior intimation for certain categories of drugs reduces bureaucratic hurdles, making it easier for manufacturers to conduct analytical and non-clinical testing.
Enhanced Regulatory Oversight: The amendments strengthen compliance requirements, ensuring that manufacturers adhere to Good Manufacturing Practices and maintain detailed records.
Improved Transparency: The updated labeling requirements will enhance transparency and traceability, ensuring that drugs are used for their intended purposes.
Encouragement for Innovation: By streamlining processes and reducing timelines, the amendments aim to encourage innovation in drug development and clinical research.

Conclusion

The New Drugs and Clinical Trials (Amendment) Rules, 2026, mark a significant step forward in modernizing India’s regulatory framework for drug development and clinical trials. By introducing prior intimation, reducing approval timelines, and enhancing compliance measures, the amendments aim to create a more efficient and transparent system that supports innovation while ensuring public safety.

These changes reflect the Government of India’s commitment to fostering a robust pharmaceutical and clinical research ecosystem, which is crucial for addressing the healthcare needs of the nation and contributing to global advancements in medicine.

In case you face any issues related to Indirect Tax-Customs, GST, Foreign Trade Policy (FTP), Arbitration matters and Central Licensing and related advisory matters in India then please feel free to get in touch with SJ EXIM Services.

We offer Legal advice and litigation support in matters related to Indirect Tax-Customs, FTP, other Indirect Tax matters & Arbitration law, all sorts of Central licensing and related matters. Come and explore the new way of doing business with us!

Source: MoHFW

Disclaimer

Handy Download:

MoHFWDownload

Connect with us for more-

@ Team S J EXIM SERVICES, New Delhi, IN

CP: Ms. Shubhra Jha, Founder

Tel: +91-11-4999 2707 I +91-9999005693

Web: www.sjexim.services

EMAIL: operations@sjexim.services I shubhra@sjexim.services

Facebook: www.facebook.com/sjeximservices

LinkedIn: https://www.linkedin.com/company/90794255/admin/feed/posts/